Global Lipodystrophy Syndrome (LS) Market (2018-2027): Historical & Forecasted Epidemiology and Key Market Trends

Dublin, Dec. 10, 2018 (GLOBE NEWSWIRE) -- The "Lipodystrophy Syndrome (LS)- Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Lipodystrophy Syndrome (LS) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Lipodystrophy Syndrome (LS) from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Epidemiology

As per Elaine Chiquette et. Al., the estimated prevalence of diagnosed Lipodystrophy Syndrome (LS) was 3.07 cases/million (95% confidence interval [CI], 2.30-4.02), 0.23 cases/million (95% CI, 0.06-0.59) and 2.84 cases/million (95% CI, 2.10-3.75) for generalized lipodystrophy (GL) and partial lipodystrophy (PL), respectively.

According to Orphanet registry, Primary lipodystrophies prevalence has been estimated at less than 1 case in 100,000.

This research estimates that the prevalent population of Lipodystrophy Syndrome (LS) will significantly change during the study period [2016-2027].

Drug Chapters

Current therapies prevent or ameliorate the comorbidities of Lipodystrophy Syndrome (LS). At present, Myalept (Bristol-Myers Squibb) (recombinant human methionyl leptin) is the only drug approved specifically for lipodystrophy. It is approved in the United States as an adjunct to diet for treatment of metabolic complications in patients with generalized lipodystrophy.

Key players such as Ionis Pharmaceuticals, Zydus Cadila and many others are involved in developing therapies for Lipodystrophy Syndrome (LS). Expected launch of emerging therapies such as Volanesorsen (Ionis Pharmaceuticals), Lipaglyn (Zydus Cadila) and some other are expected to change the treatment landscape of Lipodystrophy Syndrome (LS) in upcoming years.

Market Outlook

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Lipodystrophy Syndrome (LS) in 7MM is expected to change from the study period 2016-2027.

Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Key Topics Covered

1. Report Introduction

2. Lipodystrophy Syndrome (LS) Market Overview at a Glance
2.1. 7 Major Market Size of Lipodystrophy Syndrome (LS) in 2017
2.2. 7 Major Market Size of Lipodystrophy Syndrome (LS) in 2027

3. Disease Background and Overview: Lipodystrophy Syndrome (LS)
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis

4. Epidemiology and Patient Population
4.1. 7MM Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
4.2. 7MM Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
4.3. 7MM Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2027)

5. Lipodystrophy Syndrome (LS): Country-Wise Epidemiology
5.1. United States
5.2. Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.3. Type Specific Prevalent Cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.4. Diagnosed and treatable cases of Lipodystrophy Syndrome (LS) (2016-2027)
5.5. EU-5
5.5.1. Assumptions and Rationale
5.5.2. Germany
5.5.3. France
5.5.4. Italy
5.5.5. Spain
5.5.6. United Kingdom
5.6. Japan

6. Treatments & Medical Practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines

7. Marketed Drug
7.1.1. Myalept: Bristol-Myers Squibb
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Advantages & Disadvantages
7.1.5. Safety and Efficacy
7.1.6. Product Profile
To be continued in the report

8. Emerging Therapies
8.1. Key Cross Competition
8.1.1. Volanesorsen: Ionis Pharmaceuticals
8.1.1.1. Regulatory Milestones
8.1.1.2. Clinical Development
8.1.1.3. Product Profile
8.1.1.4. Clinical Pipeline Activity
8.1.1.4.1. Ongoing Trials Information
8.1.1.4.2. Clinical Trial by Phase
8.1.2. Lipaglyn: Zydus Cadila
8.1.2.1. Regulatory Milestones
8.1.2.2. Clinical Development
8.1.2.3. Product Profile
8.1.2.4. Clinical Pipeline Activity
8.1.2.4.1. Ongoing Trials Information
8.1.2.4.2. Clinical Trial by Phase
To be continued in report

9. Lipodystrophy Syndrome (LS) Market Size
9.1. Key Findings
9.2. Total 7MM Lipodystrophy Syndrome (LS) Market Analysis
9.2.1. Overview of Total Lipodystrophy Syndrome (LS) Market
9.2.2. Market size of Lipodystrophy Syndrome (LS) Market by 7MM (2016-2027)

10. 7MM: Country-Wise Market Analysis
10.1. United States Market Size
10.2. Germany Market Size
10.3. France Market Size
10.4. United Kingdom Market Size
10.5. Spain Market Size
10.6. Italy Market Size
10.7. Japan Market Size

11. Market Drivers

12. Market Barriers

13. Report Methodology

14. Capabilities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jrzzxs/global?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Endocrine and Metabolic Disorders Drugs